Ein Review zeigt auf: Traubensilberkerze (Cimicifuga racemosa)
                    kann auch bei Patientinnen mit Brustkrebs in der Anamnese eingesetzt
                    werden

Jennifer-Christin Kuchernig

doi:10.1055/a-1716-9591

Zeitschrift für Phytotherapie, Inhaltsverzeichnis

Zeitschrift für Phytotherapie 2022; 43(02): 62-66
DOI: 10.1055/a-1716-9591

Forschung

Ein Review zeigt auf: Traubensilberkerze (Cimicifuga racemosa) kann auch bei Patientinnen mit Brustkrebs in der Anamnese eingesetzt werden

Jennifer-Christin Kuchernig

¹Schaper & Brümmer GmbH & Co. KG, Salzgitter

Literatur
1 Robert Koch-Institut. Krebs in Deutschland für 2017/2018. 13. Ausgabe. Berlin: 2021
2 Micke O. et al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med 2008; 1: 11
3 Huebner J. et al. User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer Res 2014; 34: 943-948
4 Leitlinienprogramm Onkologie. Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 2021
5 Leitlinienprogramm Onkologie. S3-Leitlinie Komplementärmedizin in der Behandlung onkologischer PatientInnen. 2021
6 Ruan X. et al. Benefit-risk profile of black cohosh (isopropanolic Cimicifuga racemosa extract) with and without St John’s wort in breast cancer patients. Climacteric 2019; 22: 339-347
7 Jacobson JS. et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001; 19: 2739-2745
8 Rostock M. et al. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints – a prospective observational study. Gynecolo Endocrinol 2011; 27: 844-848
9 Pockaj BA. et al. Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest 2004; 22: 515-521
10 Wu X. Remifemin improve gynecological malignant tumor postoperative patients of menopause syndrome for the clinical research. Master Degree Thesis. Dalian Medical University 2011; 1-36
11 Henneicke-von Zepelin HH. et al. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. Int J Clin Pharmacol Ther 2007; 45: 143-154
12 Huang X. The clinical research of Black cohosh extract in breast cancer patients with climacteric complaints. Nanjing University of Chinese Medicine. 2011
13 Beer AM. Update Cimicifuga racemosa – neue Erkenntnisse aus Wissenschaft und Forschung: Differenzierte Evidenz für Wirksamkeit und Sicherheit von Traubensilberkerzen-Arzneimitteln zur Behandlung klimakterischer Beschwerden. Journal für Gynäkologische Endokrinologie 2014; 24: 6-10
14 Fischer J. Cimicifuga racemosa Extrakt (Remifemin^®) bei Mamma-Ca-Patientinnen mit klimakterischen Beschwerden unter hormontherapeutischer Behandlung mit Tamoxifen – eine Anwendungsbeobachtung [Dissertation]. Freiburg: Albert-Ludwigs-Universität; 2006
15 Briese V. et al. Black cohosh with or without St. John’s wort for symptom-specific climacteric treatment – results of a large-scale, controlled, observational study. Maturitas 2007; 57: 405-414
16 Beer AM. Cimicifuga in den Wechseljahren: Gibt es Risiken? . MMW – Fortschritte der Medizin 2013; 155: 22-22
17 Beer AM, Neff A. Differentiated evaluation of extract-specific evidence on Cimicifuga racemosa’s efficacy and safety for climacteric complaints. Evid Based Complement Alternat Med 2013; 2013: 860602
18 Beer AM. Cimicifuga racemosa bei klimakterischen Beschwerden – Aktuelle Daten bestätigen Wirksamkeit und Sicherheit. Z Phytother 2015; 36: 10-17
19 Li W. et al. Cimicifuga racemosa for treatment of menopausal symptoms in patients with early endometrial cancer after operation. Academic Journal of Second Military Medical University 2012; 33: 562-564
20 Chen J. et al. Efficacy and safety of remifemin on peri-menopausal symptoms induced by post-operative GnRH-a therapy for endometriosis: a randomized study versus tibolone. Med Sci Monit 2014; 20: 1950-1957
21 Lehmann-Willenbrock E, Riedel HH. Clinical and endocrinologic studies of the treatment of ovarian insufficiency manifestations following hysterectomy with intact adnexa. Zentralbl Gynakol 1988; 110: 611-618
22 Obi N. et al. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study. Cancer Epidemiol Biomarkers Prev 2009; 18: 2207-2213
23 Rebbeck TR. et al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer 2007; 120: 1523-1528
24 Henneicke-von Zepelin HH. et al. Pharmakoepidemiologische Kohortenstudie zur Anwendung von Remifemin/Remifemin plus bei Patientinnen mit Mammakarzinom, einschließlich Hormonrezeptor-positiver Tumore Interner Bericht. Studiencode SB-FEM 1400. Salzgitter: Schaper & Brümmer; 2005
25 Kostev K. Re-evaluations regarding the REMIFEMIN-study (2004) “study code: SB-FEM1400”. In: IMS Disease Analyzer. 2009
26 Hirschberg AL. et al. An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. Menopause 2007; 14: 89-96
27 Lundström E. et al. Digitized assessment of mammographic breast density – Effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo. Maturitas 2011; 70: 361-364
28 Jiang K. et al. Black cohosh improves objective sleep in postmenopausal women with sleep disturbance. Climacteric 2015; 18: 559-567
29 Li Y, Cui M, Gao S. Efficacy of remifemin for control of climacteric symptoms. Prog Obstet Gynecol 2011; 20: 462-465
30 Nappi RE. et al. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol 2005; 20: 30-35
31 Liske E. et al. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): A 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002; 11: 163-174
32 Sun N. Black cohosh improves vaginal atrophy in postmenopausal women. Academic Journal of Second Military Medical University 2012; 32: 339-341
33 Garcia-Perez MA. et al. Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line. Fertil Steril 2009; 91: 1347-1350
34 Nesselhut T, Liske E. Pharmacological measures in postmenopausal women with an isopropanolic aqueous extract of Cimicifugae racemosae rhizome Poster. 10th Annual Meeting of the North American Menopause Society (NAMS). 1999 Menopause
35 Reame NE. et al. Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause 2008; 15: 832-840
36 Bai W. et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas 2007; 58: 31-41
37 Nesselhut T. et al. Use of extract of Cimicifuga racemosa . US-Patent No. 6267994 B1. 2001
38 Bodinet C, Freudenstein J. Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Res Treat 2002; 76: 1-10
39 Hostanska K. et al. Evaluation of cell death caused by triterpene glycosides and phenolic substances from Cimicifuga racemosa extract in human MCF-7 breast cancer cells. Biol Pharm Bull 2004; 27: 1970-1975
40 Hostanska K. et al. Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis. Breast Cancer Res Treat 2004; 84: 151-160
41 Hostanska K. et al. Inhibitory effect of an isopropanolic extract of black cohosh on the invasiveness of MDA-mB 231 human breast cancer cells. In Vivo 2007; 21: 349-355
42 Osmers R. et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 2005; 105: 1074-1083
43 Uebelhack R. et al. Black cohosh and St. John’s wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006; 107: 247-255
44 Huang YX. et al. Clinical study of combined treatment of remifemin and paroxetine for perimenopausal depression. Zhonghua Yi Xue Za Zhi 2013; 93: 600-602
45 Xi S. et al. Effect of isopropanolic Cimicifuga racemosa extract on uterine fibroids in comparison with tibolone among patients of a recent randomized, double blind, parallel-controlled study in Chinese women with menopausal symptoms. Evid Based Complement Alternat Med 2014; 2014: 717686
46 Liske E. Phytokombination lindert psychovegetative Leiden. TW Gynäkologie 1997; 10: 172-175
47 Schmidt M, Polasek W, Käufeler R. Wirksamkeit und Sicherheit von Traubensilberkerze (Cimicifuga racemosa, Cimifemin^®) bei Menopausebeschwerden: Therapiebeobachtung unter Praxisbedingungen. Journal für Menopause 1/2005 27-32
48 Vermes G, Banhidy F, Acs N. The effects of remifemin on subjective symptoms of menopause. Adv Ther 2005; 22: 148-154
49 Arriaza Peso E. et al. Eficacia de Cimicifuga racemosa para el tratamiento de la clínica vasomotora y psíquica en pacientes menopáusicas. Progresos de Obstetricia y Ginecología 2008; 51: 20-27
50 Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Musterfachinformation Anastrozol. 2018
51 Arold G. et al. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John’s wort extract. Planta Med 2005; 71: 331-337
52 European Medicines Agency; Committee on Herbal Medicinal Products. Community Herbal Monograph on Hypericum perforatum L., Herba (Well-established medicinal use). EMA/HMPC/101304/2008. London: 2009